Recent Updates
Recently added Catalysts
ETON

Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference

Key Takeaway: DEER PARK, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in

Full Press Release Details

DEER PARK, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in a fireside chat at the 8th Annual SVB Leerink Healthcare Conference on Friday, March 1, 2019 at 11:30 a.m. ET in New York, NY.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDA’s 505(b)(2) regulatory pathway. Eton is primarily focused on liquid dosage forms including injectables, oral liquids and ophthalmics. Eton has a diversified pipeline of high-value product candidates in various stages of development and therapeutic areas, including multiple product candidates currently pending regulatory approval with the FDA. For more information, visit www.etonpharma.com.
Stern Investor Relations, Inc.
Last updated: Feb 21, 2019